[8-K] Nutex Health, Inc. Reports Material Event

Nutex Health Inc. filed an 8‑K announcing it issued a press release with anticipated preliminary financial metrics for the period ended September 30, 2025, furnished as Exhibit 99.1.

Rhea-AI Filing Summary

Nutex Health Inc. filed an 8‑K announcing it issued a press release with anticipated preliminary financial metrics for the period ended September 30, 2025, furnished as Exhibit 99.1.

The company also updated its Nasdaq listing status. Nutex is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to not timely filing its Quarterly Report on Form 10‑Q for the period ended June 30, 2025. The company submitted a compliance plan on October 15, 2025, and Nasdaq granted an extension on October 16, 2025 to file the June 30, 2025 Form 10‑Q by December 12, 2025. If Nutex does not file by December 12, 2025, Nasdaq staff will issue a delisting notice, which the company may appeal to a Nasdaq Hearings Panel.

Insights

Listing & Compliance Analyst

Nasdaq grants filing extension to Dec 12, 2025; delisting risk if missed.

Nutex Health disclosed non‑compliance with Nasdaq Listing Rule 5250(c)(1) because it did not timely file its Form 10‑Q for the period ended June 30, 2025. The company submitted a plan on October 15, 2025, and Nasdaq granted an extension on October 16, 2025.

The extension sets a hard deadline of December 12, 2025 to file the delinquent report. If the deadline is missed, Nasdaq staff will issue a delisting notice; Nutex may appeal to a Nasdaq Hearings Panel.

Actual impact depends on whether the June 30, 2025 Form 10‑Q is filed by December 12, 2025. The 8‑K also furnished a press release with anticipated preliminary metrics for the period ended September 30, 2025.

8-K Event Classification

3 items: 2.02, 3.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NUTX announce in its 8‑K?

Nutex Health furnished a press release with anticipated preliminary financial metrics for the period ended September 30, 2025 and updated its Nasdaq compliance status.

Why is NUTX out of compliance with Nasdaq?

The company did not timely file its Quarterly Report on Form 10‑Q for the period ended June 30, 2025, breaching Nasdaq Listing Rule 5250(c)(1).

What is the new deadline for NUTX to regain compliance?

Nasdaq granted an extension to file the June 30, 2025 Form 10‑Q by December 12, 2025.

What happens if NUTX misses the December 12, 2025 deadline?

Nasdaq staff will issue a delisting notice, which the company may appeal to a Nasdaq Hearings Panel.

When did NUTX submit its compliance plan to Nasdaq?

Nutex submitted a plan on October 15, 2025; Nasdaq granted the extension on October 16, 2025.

What exchange and symbol does NUTX trade on?

Nutex Health’s common stock trades on The Nasdaq Stock Market LLC under the symbol NUTX.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/20/2025 - 07:09 AM Learn about SEC filing dates

0001479681FALSE00014796812025-10-202025-10-20

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): October 20, 2025 

NUTEX HEALTH INC.  

(Exact name of registrant as specified in its charter) 

Delaware			001-41346			11-3363609
(State or Other Jurisdiction  of Incorporation)			(Commission File Number)			(I.R.S. Employer  Identification No.)

  

6030 S. Rice Ave, Suite C, Houston, Texas 77081 

(Address of principal executive offices) (zip code) 

(713) 660-0557 

(Registrant’s telephone number, including area code) 

N/A 

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

NUTX

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 20, 2025, Nutex Health Inc. (the “Company”) issued a press release containing certain anticipated preliminary financial metrics with respect to the period ended September 30, 2025 and other information. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on August 20, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “June 30, 2025 Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC.

On October 15, 2025, in response to the Notice, the Company submitted to Nasdaq a plan to regain compliance with the Rule and requested an extension from the due date of its delinquent June 30, 2025 Form 10-Q until December 12, 2025, which request was granted by Nasdaq on October 16, 2025. In the event the Company is not able to file the June 30, 2025 Form 10-Q with the SEC on or before December 12, 2025, the staff of Nasdaq will issue a delisting notice, which the Company may appeal to a Nasdaq Hearings Panel.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.			Description of Exhibit
99.1			Press Release dated October 20, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: October 20, 2025			NUTEX HEALTH INC.
			By:			/s/ Jon C. Bates
						Jon C. Bates  Chief Financial Officer